GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Owner Earnings per Share (TTM)
中文

Co-Diagnostics (Co-Diagnostics) Owner Earnings per Share (TTM) : -1.08 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Co-Diagnostics Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Co-Diagnostics's Owner Earnings per Share (TTM) ended in Dec. 2023 was $-1.08. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Co-Diagnostics's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 9 years, the highest Price-to-Owner-Earnings ratio of Co-Diagnostics was 58.98. The lowest was 4.24. And the median was 6.49.


CODX's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.79
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Co-Diagnostics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.50. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.21. It's PE Ratio ratio for today is At Loss.

Co-Diagnostics's EPS without NRI for the three months ended in Dec. 2023 was $-0.52. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.30. It's PE Ratio without NRI ratio for today is At Loss.


Co-Diagnostics Owner Earnings per Share (TTM) Historical Data

The historical data trend for Co-Diagnostics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Owner Earnings per Share (TTM) Chart

Co-Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only - 0.87 1.16 -0.42 -1.08

Co-Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.96 -1.26 -1.55 -1.08

Competitive Comparison of Co-Diagnostics's Owner Earnings per Share (TTM)

For the Medical Devices subindustry, Co-Diagnostics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Price-to-Owner-Earnings falls into.



Co-Diagnostics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Co-Diagnostics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -35.33
Depreciation, Depletion and Amortization 1.23
Change In Deferred Tax -2.42
5Y Average of Maintenance Capital Expenditure 0.99
Change In Working Capital 5.64
Shares Outstanding (Diluted Average) 29.47

1. Start with "Net Income" from income statement. Co-Diagnostics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-35.33 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Co-Diagnostics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $1.23 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Co-Diagnostics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.42 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.99 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Co-Diagnostics's 5-Year Average Maintenance Capital Expenditure = $0.99 Mil

5. "Change In Working Capital" is from cashflow statement. Co-Diagnostics's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $5.64 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Co-Diagnostics's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 29.467 Mil.

Co-Diagnostics's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -35.332 +1.23+-2.419
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.99254509162763+5.642)/29.467
=-1.08

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.14/-1.08
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Co-Diagnostics Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Co-Diagnostics (Co-Diagnostics) Business Description

Traded in Other Exchanges
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
Executives
Brian Lee Brown officer: Chief Financial Officer 5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy director 64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan director, officer: CEO and President 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson director 26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson officer: CFO and Secretary 7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield director, officer: Chief Science Officer 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc 10 percent owner 1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner director 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc 10 percent owner 8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc 10 percent owner 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124